Subependymal giant cell astrocytoma epidemiology and demographics: Difference between revisions
Jump to navigation
Jump to search
| Line 6: | Line 6: | ||
==Prevalence== | ==Prevalence== | ||
*Approximately 10-20% of patients with [[tuberous sclerosis]] develop subependymal giant cell astrocytoma. | *Approximately 10-20% of patients with [[tuberous sclerosis]] develop subependymal giant cell astrocytoma.<ref name="RothRoach2013">{{cite journal|last1=Roth|first1=Jonathan|last2=Roach|first2=E. Steve|last3=Bartels|first3=Ute|last4=Jóźwiak|first4=Sergiusz|last5=Koenig|first5=Mary Kay|last6=Weiner|first6=Howard L.|last7=Franz|first7=David N.|last8=Wang|first8=Henry Z.|title=Subependymal Giant Cell Astrocytoma: Diagnosis, Screening, and Treatment. Recommendations From the International Tuberous Sclerosis Complex Consensus Conference 2012|journal=Pediatric Neurology|volume=49|issue=6|year=2013|pages=439–444|issn=08878994|doi=10.1016/j.pediatrneurol.2013.08.017}}</ref> | ||
==Incidence== | ==Incidence== | ||
Revision as of 19:33, 4 November 2015
|
Subependymal giant cell astrocytoma Microchapters |
|
Differentiating Subependymal Giant Cell Astrocytoma from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Subependymal giant cell astrocytoma epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Subependymal giant cell astrocytoma epidemiology and demographics |
|
FDA on Subependymal giant cell astrocytoma epidemiology and demographics |
|
CDC on Subependymal giant cell astrocytoma epidemiology and demographics |
|
Subependymal giant cell astrocytoma epidemiology and demographics in the news |
|
Blogs on Subependymal giant cell astrocytoma epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sujit Routray, M.D. [2]
Overview
Prevalence
- Approximately 10-20% of patients with tuberous sclerosis develop subependymal giant cell astrocytoma.[1]
Incidence
- The incidence of subependymal giant cell astrocytoma is approximately 2.5 per 100,000 individuals in the United States.[1]
Age
- The mean age at diagnosis is 13 years.[2]
Gender
- Males are more commonly affected with subependymal giant cell astrocytoma than females.[3]
Race
Reference
- ↑ 1.0 1.1 Roth, Jonathan; Roach, E. Steve; Bartels, Ute; Jóźwiak, Sergiusz; Koenig, Mary Kay; Weiner, Howard L.; Franz, David N.; Wang, Henry Z. (2013). "Subependymal Giant Cell Astrocytoma: Diagnosis, Screening, and Treatment. Recommendations From the International Tuberous Sclerosis Complex Consensus Conference 2012". Pediatric Neurology. 49 (6): 439–444. doi:10.1016/j.pediatrneurol.2013.08.017. ISSN 0887-8994.
- ↑ Nabbout, R; Santos, M; Rolland, Y; Delalande, O; Dulac, O; Chiron, C (1999). "Early diagnosis of subependymal giant cell astrocytoma in children with tuberous sclerosis". Journal of Neurology, Neurosurgery & Psychiatry. 66 (3): 370–375. doi:10.1136/jnnp.66.3.370. ISSN 0022-3050.
- ↑ Campen CJ, Porter BE (2011). "Subependymal Giant Cell Astrocytoma (SEGA) Treatment Update". Curr Treat Options Neurol. 13 (4): 380–5. doi:10.1007/s11940-011-0123-z. PMC 3130084. PMID 21465222.